Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
about
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancerEpigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancerHDAC inhibition decreases the expression of EGFR in colorectal cancer cells.Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms.Epigenetics as a therapeutic target in breast cancer.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Epigenomics and breast cancerPropolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of ActionActivation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.Oestrogen receptor negativity in breast cancer: a cause or consequence?Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.Hydroxamic acids (therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling.Breast cancer stem cells and their role in resistance to endocrine therapy.Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.Epigenetic mechanisms of breast cancer: an update of the current knowledge.Entinostat: a promising treatment option for patients with advanced breast cancer.Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.CHD5 is down-regulated through promoter hypermethylation in gastric cancer.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.Histone Deacetylase Inhibitors and Diabetic Kidney Disease
P2860
Q28743229-4DBE652B-E064-460A-B2F2-EEB277CF6972Q33585930-C133D286-0EED-4DC5-B12B-31AB3E520DF4Q33862612-6F4E2917-BA4E-4157-8D53-940F02BFD7A3Q34417159-C7C49F80-841A-4250-967E-467B7808AC1AQ34793432-790A9689-1276-468F-BD48-9C276E1256C9Q35911749-BB5C3DD3-E1AE-4B45-A5BA-B1884D714D7DQ36205231-B1143D86-A45A-4B95-8123-EF3356CAB7BCQ36449057-4FA6EC10-8752-498E-8212-2CE53E883683Q36589865-5E8AE573-F0CA-4CA9-9EC5-07949D190C4AQ37078784-1BD0254B-B40E-49FB-9AE1-F374417B177EQ37503537-85D0F573-28E7-4B1F-A01F-2970C68441F4Q37521175-AC712FB3-38CF-4B60-84C1-E6B5F4357519Q37529397-DCE18515-31D6-466D-BDC8-1C0817EFD122Q37632279-81A789CA-9007-4D63-907A-2DF81D9103AEQ37768771-1330145A-1E0B-4EDF-B77F-B250D58ADF94Q37901429-28124C09-F772-4BEC-9296-9A970566FEB9Q37962586-F6CDA4C7-F11D-49E7-A635-0A611079325FQ38296760-CE641B4B-D0D7-4D3C-86EB-454CF353F0A6Q38741783-A8B7DF9C-852D-4353-900D-82F6435F3C55Q38990723-4CF66D23-73FF-4E00-B837-E26460744256Q39396340-CE713649-E2B7-4841-A318-6AECAE16596EQ39586909-FD412676-97A9-46BA-B68B-F9672DF22A19Q40952382-EDEF4903-C6CE-4125-816D-84A9960EB0A1Q41042385-04D753E8-6947-4C69-9F28-A960BCAD9657Q42602377-6B70CD62-C30A-4C49-8639-CC5D8D283B44Q42755954-6DFCFDC4-57A3-4B00-BB9A-D2E7128960FEQ53669221-38E653E9-705F-401F-9046-C1BE6300CD15Q58762435-9132D2BD-8E77-441E-907D-597E758A755B
P2860
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@en
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@nl
type
label
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@en
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@nl
prefLabel
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@en
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@nl
P2093
P1476
Inhibition of histone deacetyl ...... ive human breast cancer cells.
@en
P2093
Nancy E Davidson
Patrick G Shaw
P2860
P2888
P304
P356
10.1007/S10549-008-0148-5
P407
P577
2008-08-06T00:00:00Z